Evidence map›Paper›PMID 34341460›Full record

ArticleScientific reports2021

KUS121 attenuates the progression of monosodium iodoacetate-induced osteoarthritis in rats.

Sachiko Iwai, Hanako O Ikeda, Hisashi Mera, Kohei Nishitani, Motoo Saito, Akitaka Tsujikawa, Akira Kakizuka

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sachiko IwaiDepartment of Ophthalmology and Visual Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hanako O IkedaDepartment of Ophthalmology and Visual Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan. hanakoi@kuhp.kyoto-u.ac.jp.
Hisashi MeraUonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan.
Kohei NishitaniDepartment of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Motoo SaitoDepartment of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akitaka TsujikawaDepartment of Ophthalmology and Visual Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akira KakizukaLaboratory of Functional Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan.
Kyoto University · JPNiigata University Medical and Dental Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently there is no effective treatment available for osteoarthritis (OA). We have recently developed Kyoto University Substances (KUSs), ATPase inhibitors specific for valosin-containing protein (VCP), as a novel class of medicine for cellular protection. KUSs suppressed intracellular ATP depletion, endoplasmic reticulum (ER) stress, and cell death. In this study, we investigated the effects of KUS121 on chondrocyte cell death. In cultured chondrocytes differentiated from ATDC5 cells, KUS121 suppressed the decline in ATP levels and apoptotic cell death under stress conditions induced by TNFα. KUS121 ameliorated TNFα-induced reduction of gene expression in chondrocytes, such as Sox9 and Col2α. KUS121 also suppressed ER stress and cell death in chondrocytes under tunicamycin load. Furthermore, intraperitoneal administration of KUS121 in vivo suppressed chondrocyte loss and proteoglycan reduction in knee joints of a monosodium iodoacetate-induced OA rat model. Moreover, intra-articular administration of KUS121 more prominently reduced the apoptosis of the affected chondrocytes. These results demonstrate that KUS121 protects chondrocytes from stress-induced cell death in vitro and in vivo, and indicate that KUS121 is a promising novel therapeutic agent to prevent the progression of OA.

Indexed as

ApoptosisChondrocytesEndoplasmic Reticulum StressOsteoarthritisAdenosine TriphosphateAnimalsCell LineCollagen Type IIDisease Models, AnimalDisease ProgressionIodoacetatesIodoacetic AcidMaleMiceNaphthalenesPyridinesAdenosine TriphosphateCollagen Type IIIodoacetatesIodoacetic AcidKUS121NaphthalenesPyridinesSox9 protein, ratSOX9 Transcription FactorSulfonic AcidsTumor Necrosis Factor-alpha

Identifiers

PMID34341460
PMCPMC8329178
OpenAlexW3192467655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.